{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:50:55Z","timestamp":1790974255242,"version":"4.1.0"},"reference-count":81,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Follicular lymphomas (FL) are neoplasms that resemble normal germinal center (GC) B-cells. Normal GC and neoplastic follicles contain non-neoplastic cells such as T-cells, follicular dendritic cells, cancer associated fibroblasts, and macrophages, which define the tumor microenvironment (TME), which itself is an essential factor in tumor cell survival. The main characteristics of the TME in FL are an increased number of follicular regulatory T-cells (Treg) and follicular helper T-cells (Tfh), M2-polarization of macrophages, and the development of a nodular network by stromal cells that creates a suitable niche for tumor growth. All of them play important roles in tumor angiogenesis, inhibition of apoptosis, and immune evasion, which are key factors in tumor progression and transformation risk. Based on these findings, novel therapies have been developed to target specific mutations present in the TME cells, restore immune suppression, and modulate TME.<\/jats:p>","DOI":"10.3390\/cancers14092158","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T11:45:55Z","timestamp":1650973555000},"page":"2158","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Unveiling the Role of the Tumor Microenvironment in the Treatment of Follicular Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"given":"Mariola","family":"Blanco","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Collazo-Lorduy","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-0176","authenticated-orcid":false,"given":"Natalia","family":"Yanguas-Cas\u00e1s","sequence":"additional","affiliation":[{"name":"Lymphoma Research Group, Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, IDIPHISA, CIBERFES, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3503-4847","authenticated-orcid":false,"given":"Virginia","family":"Calvo","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Provencio","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, 28222 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004\u20132014: Sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1200\/JCO.2012.48.3990","article-title":"Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: A report from the University of Iowa\/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource","volume":"31","author":"Link","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.seminoncol.2018.07.005","article-title":"New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs","volume":"45","author":"Devan","year":"2018","journal-title":"Semin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Roy","year":"2004","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-385991-4.00001-5","article-title":"Early steps of follicular lymphoma pathogenesis","volume":"111","author":"Roulland","year":"2011","journal-title":"Adv. Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"106684","DOI":"10.1016\/j.intimp.2020.106684","article-title":"Prognostic value of tissue-infiltrating immune cells in tumor microenvironment of follicular lymphoma: A meta-analysis","volume":"85","author":"Xie","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1200\/JCO.2013.52.8190","article-title":"t(14;18) Translocation: A predictive blood biomarker for follicular lymphoma","volume":"32","author":"Roulland","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1084\/jem.20102477","article-title":"A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center","volume":"208","author":"Schwickert","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1146\/annurev.iy.12.040194.001001","article-title":"Germinal centers","volume":"12","author":"MacLennan","year":"1994","journal-title":"Annu. Rev. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/354389a0","article-title":"Intraclonal generation of antibody mutants in germinal centres","volume":"354","author":"Jacob","year":"1991","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/0167-5699(94)90269-0","article-title":"The role of CD40 in the regulation of humoral and cell-mediated immunity","volume":"15","author":"Durie","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Watanabe, T. (2021). The Tumor Microenvironment in Follicular Lymphoma: Its Pro-Malignancy Role with Therapeutic Potential. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22105352"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/nm.2426","article-title":"Follicular regulatory T cells expressing Foxp3 and Bcl-6 suppress germinal center reactions","volume":"17","author":"Chung","year":"2011","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"6185","DOI":"10.4049\/jimmunol.1101440","article-title":"Is there a typical germinal center? A large-scale immunohistological study on the cellular composition of germinal centers during the hapten-carrier-driven primary immune response in mice","volume":"187","author":"Wittenbrink","year":"2011","journal-title":"J. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/CCO.0b013e32833d5938","article-title":"Implications of the tumor microenvironment on survival and disease response in follicular lymphoma","volume":"22","author":"Gribben","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1126\/science.3874430","article-title":"Involvement of the bcl-2 gene in human follicular lymphoma","volume":"228","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1182\/blood-2017-11-764365","article-title":"Critical influences on the pathogenesis of follicular lymphoma","volume":"131","author":"Stevenson","year":"2018","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1126\/science.3929382","article-title":"The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining","volume":"229","author":"Tsujimoto","year":"1985","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1182\/blood.V85.9.2528.bloodjournal8592528","article-title":"Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals","volume":"85","author":"Limpens","year":"1995","journal-title":"Blood"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1182\/blood-2012-03-415380","article-title":"Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas","volume":"120","author":"Victora","year":"2012","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1182\/blood.V91.12.4708","article-title":"Follicular lymphomas contain a clonally linked but phenotypically distinct neoplastic B-cell population in the interfollicular zone","volume":"91","author":"Dogan","year":"1998","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1182\/blood-2011-11-367730","article-title":"Follicular lymphoma and the immune system: From pathogenesis to antibody therapy","volume":"119","author":"Stevenson","year":"2012","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.semcancer.2013.08.001","article-title":"The yin and the yang of follicular lymphoma cell niches: Role of microenvironment heterogeneity and plasticity","volume":"24","author":"Tarte","year":"2014","journal-title":"Semin. Cancer Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/asheducation-2014.1.158","article-title":"Indolent lymphoma: Follicular lymphoma and the microenvironment-insights from the microscope","volume":"2014","author":"Harris","year":"2014","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1182\/blood-2006-04-018218","article-title":"High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma","volume":"108","author":"Carreras","year":"2006","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1038\/leu.2011.301","article-title":"Characterization of intratumoral follicular helper T cells in follicular lymphoma: Role in the survival of malignant B cells","volume":"26","author":"Yssel","year":"2012","journal-title":"Leukemia"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2006-05-020800","article-title":"Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: Role of stromal cells in follicular lymphoma pathogenesis","volume":"109","author":"Monvoisin","year":"2007","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/10428194.2016.1263841","article-title":"An analysis of the role of follicular lymphoma-associated fibroblasts to promote tumor cell viability following drug-induced apoptosis","volume":"58","author":"Staiger","year":"2017","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Boutilier, A.J., and Elsawa, S.F. (2021). Macrophage Polarization States in the Tumor Microenvironment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22136995"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/hon.2855","article-title":"Vulnerabilities in the tumor and microenvironment in follicular lymphoma","volume":"39","author":"Campo","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2249.2011.04515.x","article-title":"Immunology in the clinic review series; focus on cancer: Tumour-associated macrophages: Undisputed stars of the inflammatory tumour microenvironment","volume":"167","author":"Allavena","year":"2012","journal-title":"Clin. Exp. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3389\/fphys.2014.00075","article-title":"Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis","volume":"5","author":"Riabov","year":"2014","journal-title":"Front. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/cbin.10788","article-title":"M2 macrophages induce EMT through the TGF-\u03b2\/Smad2 signaling pathway","volume":"41","author":"Zhu","year":"2017","journal-title":"Cell Biol. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1158\/1078-0432.CCR-14-3253","article-title":"The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association","volume":"21","author":"Kridel","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2004-06-2298","article-title":"Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment","volume":"105","author":"Glas","year":"2005","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial","volume":"26","author":"Canioni","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"72818","DOI":"10.18632\/oncotarget.20350","article-title":"Neutrophils protect lymphoma cells against cytotoxic and targeted therapies through CD11b\/ICAM-1 binding","volume":"8","author":"Hirz","year":"2017","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood-2009-02-202465","article-title":"A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients","volume":"114","author":"Gentles","year":"2009","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/01.LAB.0000053913.85892.E9","article-title":"Gene expression profile of serial samples of transformed B-cell lymphomas","volume":"83","author":"Hofmann","year":"2003","journal-title":"Lab. Investig. J. Technol. Methods Pathol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2012.44.2137","article-title":"Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation","volume":"31","author":"Kiaii","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1158\/1078-0432.CCR-13-2367","article-title":"Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma","volume":"20","author":"Smeltzer","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.2008.18.0513","article-title":"High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma","volume":"27","author":"Carreras","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/cas.13873","article-title":"Pyruvate secreted from patient-derived cancer-associated fibroblasts supports survival of primary lymphoma cells","volume":"110","author":"Sakamoto","year":"2019","journal-title":"Cancer Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: A multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hon.2589","article-title":"Treating Hodgkin lymphoma in the new millennium: Relapsed and refractory disease","volume":"37","author":"LaCasce","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e281","DOI":"10.1038\/bcj.2015.1","article-title":"PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survival","volume":"5","author":"Yang","year":"2015","journal-title":"Blood Cancer J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","article-title":"Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial","volume":"15","author":"Westin","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1182\/blood.2019004753","article-title":"Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed\/refractory follicular lymphoma","volume":"137","author":"Armand","year":"2021","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1158\/1078-0432.CCR-19-0438","article-title":"A Phase I Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed\/Refractory B-Cell Lymphoma","volume":"25","author":"Tuscano","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"61425","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1(+) T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/bjh.12630","article-title":"Phase IA\/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma","volume":"164","author":"Fanale","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/ajh.25757","article-title":"Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma","volume":"95","author":"Timmerman","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/bjh.12755","article-title":"Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma","volume":"165","author":"Tuscano","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S1470-2045(14)70455-3","article-title":"Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: An open-label, phase 2 trial","volume":"15","author":"Fowler","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/S2352-3026(19)30089-4","article-title":"Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): A multicentre, single-arm, phase 2 study","volume":"6","author":"Morschhauser","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1182\/blood-2018-05-853499","article-title":"An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed\/refractory follicular B-cell lymphoma","volume":"132","author":"Morschhauser","year":"2018","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1182\/bloodadvances.2020001584","article-title":"PI3K\u03b4 inhibition reshapes follicular lymphoma-immune microenvironment cross talk and unleashes the activity of venetoclax","volume":"4","author":"Serrat","year":"2020","journal-title":"Blood Adv."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.3324\/haematol.2016.151738","article-title":"Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: A subgroup analysis of a phase 2 study","volume":"102","author":"Salles","year":"2017","journal-title":"Haematologica"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1182\/blood-2017-05-786566","article-title":"Duvelisib, a novel oral dual inhibitor of PI3K-\u03b4,\u03b3, is clinically active in advanced hematologic malignancies","volume":"131","author":"Flinn","year":"2018","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1200\/JCO.18.00915","article-title":"DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma","volume":"37","author":"Flinn","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1200\/JCO.20.03433","article-title":"Umbralisib, a Dual PI3K\u03b4\/CK1\u03b5 Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma","volume":"39","author":"Fowler","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood-2011-09-379214","article-title":"Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling","volume":"119","author":"Hume","year":"2012","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3389\/fimmu.2020.00018","article-title":"Advances in Anti-Tumor Treatments Targeting the CD47\/SIRP\u03b1 Axis","volume":"11","author":"Zhang","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin\u2019s Lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Boss","year":"2015","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1158\/2159-8290.CD-16-1417","article-title":"The CREBBP Acetyltransferase Is a Haploinsufficient Tumor Suppressor in B-cell Lymphoma","volume":"7","author":"Zhang","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.12819","article-title":"A multicentre phase II study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma","volume":"165","author":"Ogura","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1078-0432.CCR-15-0624","article-title":"A Phase I\/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed\/Refractory Lymphoma","volume":"22","author":"Evens","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/S1470-2045(20)30441-1","article-title":"Tazemetostat for patients with relapsed or refractory follicular lymphoma: An open-label, single-arm, multicentre, phase 2 trial","volume":"21","author":"Morschhauser","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-136653","article-title":"A phase-2, open-label, multienter study of tazemetostat in combination with rituximab for the treatment of relapsed or refractory follicular lymphoma","volume":"136","author":"Patel","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/s41467-020-20488-3","article-title":"CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin\u2019s lymphoma and tumor-supportive follicular T helper cells","volume":"12","author":"Bunse","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2158\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:01:15Z","timestamp":1760137275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/9\/2158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":81,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["cancers14092158"],"URL":"https:\/\/doi.org\/10.3390\/cancers14092158","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]}}}